Finanzen von Tyra Biosciences Inc (TYRA)TYRATyra Biosciences Inc

Evaluating the bottom line, Tyra Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.31%, provide a clear picture of how effectively TYRA converts its operational activities into shareholder value.

In the context of the broader market, TYRA competes directly with industry leaders such as ABSI and TRAX. With a market capitalization of $1.51B, it holds a significant position in the sector. When comparing efficiency, TYRA's gross margin of N/A stands against ABSI's 100.00% and TRAX's N/A. Such benchmarking helps identify whether Tyra Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Tyra has reported significant net losses, with Q2 2026 showing a net income loss of -$45.56 million and an EPS of -0.69. The company has strong cash reserves of $353.9 million, which should support operations into 2028, but ongoing losses are a concern.